NCT01819389View on ClinicalTrials.gov

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

PHASE3CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions

Leukemia, Myeloid, Chronic, BCR-ABL Positive

Interventions

DRUG

Imatinib and Nilotinib

Trial Locations (1)

64460

"Servicio de Hematologia, Hospital Universitario José E. Gonzalez", Monterrey

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Hospital Universitario Dr. Jose E. Gonzalez

OTHER